2-(3-chlorophenyl)-5-methylfuran | 918299-51-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-chlorophenyl)-5-methylfuran
• 英文别名: 2-(m-chlorophenyl)-5-methylfuran
• CAS: 918299-51-1
• 化学式: C₁₁H₉ClO
• 分子量: 192.645
• InChiKey: HCVJGBVPALAAKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-氯苯甲醛 在 正丁基锂 、 苯甲酸 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 26.0h， 生成 2-(3-chlorophenyl)-5-methylfuran
  参考文献：
  名称：

  2,5-Disubstituted furans from 1,4-alkynediols

  摘要：

  1-4-Alkynediols serve as readily available starting materials for isomerisation to 1,4-diketones, which can be converted in situ into the corresponding furans by acid-catalysed dehydration. A range of 2,5-disubstituted furans was prepared using the ruthenium-based catalyst Ru(PPh3)(3)(CO)H-2 with Xantphos at 1 mol % loading. (C) 2007 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2007.05.069

文献信息

• PHARMACEUTICAL COMPOSITION COMPRISING PYRAZOLONE DERIVATIVE
  申请人：Genecare Research Institute Co., Ltd

  公开号：EP1900728A1

  公开（公告）日：2008-03-19

  The present invention relates to pharmaceutical compositions containing a compound represented by formula (I), or a pharmaceutically acceptable prodrug or salt thereof, or a hydrate or solvate thereof as an active ingredient, (wherein, R1, R2, R3, and R4 are the same as R1, R2, R3, and R4 in the description of the present invention).

  本发明涉及含有由式(I)所代表的化合物、其药用可接受的前药或盐、或其水合物或溶剂和作为活性成分的药物组合物（其中，R1、R2、R3和R4与本发明描述中的R1、R2、R3和R4相同）。
• [EN] POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AND COMBINATION THERAPY<br/>[FR] POTENTIALISATEURS D'ANTIBIOTIQUES DE TYPE BÊTA-LACTAMES ET POLYTHÉRAPIE
  申请人：UNIV NOTRE DAME DU LAC

  公开号：WO2017106552A1

  公开（公告）日：2017-06-22

  Proteins of methicillin-resistant Staphylococcus aureus (MRSA), an antibiotic sensor/signal transducer, are phosphorylated on exposure to β-lactam antibiotics. This event is critical for the onset of the biochemical events that unleash induction of antibiotic resistance. The phosphorylation and the antibiotic-resistance phenotype can be abrogated in the presence of inhibitors described herein that restore susceptibility of the organism to β- lactam antibiotics. The invention thus provides compounds and methods for abrogating antibiotic resistance to β-lactam antibiotics and for treating infections causes by antibiotics prone to developing resistance by potentiating β-lactam antibiotics.

  耐甲氧西林金黄色葡萄球菌（MRSA）的蛋白质是一种抗生素感应器/信号传导体，在暴露于β-内酰胺类抗生素时会发生磷酸化。这一事件对于引发生物化学事件的开始至关重要，从而诱导抗生素抗性。在本文所述的抑制剂存在的情况下，磷酸化和抗生素抗性表型可以被废除，从而恢复该生物对β-内酰胺类抗生素的敏感性。因此，该发明提供了化合物和方法，用于废除对β-内酰胺类抗生素的抗性，并通过增强β-内酰胺类抗生素来治疗由易于产生抗性的抗生素引起的感染。
• 1,4-Carbonylative addition of arylboronic acids to methyl vinyl ketone: a new synthetic tool for rapid furan and pyrrole synthesis
  作者：Hélène Chochois、Mathieu Sauthier、Eddy Maerten、Yves Castanet、André Mortreux

  DOI：10.1016/j.tet.2006.09.035

  日期：2006.12

  The rhodium catalysed 1,4-carbonylative addition of arylboronic acids to methyl vinyl ketone under carbon monoxide pressure was studied. High yields of 1,4-diketones were obtained using a catalytic system formed from Rh(COD)2BF4 (COD=1,5-cyclooctadiene) and triphenylphosphine even at very low catalyst loading (0.02 mol %). A short synthetic procedure combining this carbonylation reaction with a subsequent

  研究了一氧化碳压力下铑在甲基乙烯基酮上铑催化的1，4-羰基芳基硼酸加成反应。使用由Rh（COD）2 BF 4（COD = 1,5-环辛二烯）和三苯膦形成的催化体系，即使在非常低的催化剂负载量（0.02 mol％）下也能获得高产率的1,4-二酮。将该羰基化反应与随后的环化步骤结合起来的简短合成程序提供了吡咯或呋喃。
• Plasminogen Activator Inhibitor-1 Inhibitor
  申请人：Muto Susumu

  公开号：US20070276011A1

  公开（公告）日：2007-11-29

  A medicament having inhibitory activity against plasminogen activator inhibitor-1, which comprises as an active ingredient a compound represented by the following general formula (I) or a salt thereof: wherein R 1 and R 2 represents an aromatic group which may be substituted, W represents a group selected from the following connecting group W-1: (wherein a bond at the left end binds to the carbon atom and a bond at the right end binds to the nitrogen atom, X represents sulfur atom or NH, Y represents oxygen atom or sulfur atom, R 3 represents a hydrocarbon group, hydroxy group, or carboxy group), Z represents a single bond or a connecting group wherein a number of atoms in a main chain is 1 to 3.

  一种具有抑制纤溶酶原激活物抑制剂-1活性的药物，其包含以下通式（I）或其盐作为活性成分的化合物：其中R1和R2代表可以被取代的芳香基团，W代表以下连接基团之一：（其中左端的键结合到碳原子，右端的键结合到氮原子，X代表硫原子或NH，Y代表氧原子或硫原子，R3代表烃基团，羟基或羧基），Z代表单键或连接基团，其中主链中的原子数为1到3。
• PYRAZOLONE DERIVATIVE
  申请人：Genecare Research Institute Co., Ltd

  公开号：EP1905762A1

  公开（公告）日：2008-04-02

  The present invention relates to compounds represented by formula (I), or pharmaceutically acceptable prodrugs or salts thereof, or hydrates or solvates thereof, (wherein, R1, R2, R3, and R4 are the same as R1, R2, R3, and R4 in the description of the present invention).

  本发明涉及由式(I)表示的化合物，其药学上可接受的前药或盐，或其水合物或溶剂化物，其中，R1、R2、R3和R4与本发明说明中的R1、R2、R3和R4相同。